We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00417833
First Posted: January 4, 2007
Last Update Posted: October 20, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Asociación para Evitar la Ceguera en México
  Purpose

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.


Condition Intervention Phase
Diabetic Proliferative Retinopathy Vascular Vein Oclussion Choroidal Neovascularization Drug: Intravitreal Bevacizumab Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Study Start Date: December 2005
Estimated Study Completion Date: July 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
  • Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
  • Completely studies

Exclusion Criteria:

Complications

  • Tractional Detachment
  • Endophthalmitis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417833


Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Myrian L Hernández, MD Asociación para Evitar la Ceguera en México
  More Information

ClinicalTrials.gov Identifier: NCT00417833     History of Changes
Other Study ID Numbers: APEC-0017
First Submitted: January 3, 2007
First Posted: January 4, 2007
Last Update Posted: October 20, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents